QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文 FRONTIERS IN ONCOLOGY, 2022, 卷号: 12 作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin 收藏  |  浏览/下载：18/0  |  提交时间：2022/05/16 Sarcoid-like reaction  immune checkpoint inhibitor  Toripalimab  PD-1  case report   The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者:  Wang, Wenxian;  Gu, Xiaodong;  Wang, Liping;  Pu, Xingxiang;  Feng, Huijing 收藏  |  浏览/下载：26/0  |  提交时间：2022/01/10 Non-small cell lung cancer  PD-L1  Immune checkpoint inhibitor  Immune-related adverse event   Safety and efficacy of combination therapy using programmed cell death protein-1/programmed cell death ligand-1 inhibitors and radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis 期刊论文 CANCER MEDICINE, 2021, 页码: 19 作者:  Geng, Yichao;  Zhang, Qiuning;  Feng, Shuangwu;  Li, Chengcheng;  Wang, Lina 收藏  |  浏览/下载：26/0  |  提交时间：2021/12/10 combined radio-immunotherapy  meta-analysis  non-small-cell lung cancer  programmed cell death protein-1/programmed cell death ligand-1 inhibitors  radiotherapy  systematic review   Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis 期刊论文 BMC CANCER, 2019, 卷号: 19 作者:  Zhou, Min;  Sun, Xiaoying;  Roudi, Raheleh;  Dai, Ting;  Chen, Shangya 收藏  |  浏览/下载：40/0  |  提交时间：2019/12/05 Non-small cell lung cancer  Oncology  Programmed cell death protein-1  Programmed cell death ligand 1  Inhibitor  Immune-related adverse event  Meta-analysis  Systematic review